Prof Paola Patrignani PhD

Current position:
Professor of Pharmacology, Department of Neuroscience, Imaging and Clinical Sciences, Section of Cardiovascular and Pharmacological Sciences, "G. d’Annunzio" University, Chieti, Italy.
E-mail: ppatrignani@unich.it
***************

Paola Patrignani was graduated at the Faculty of Biological Sciences, "La Sapienza" University of Rome (Italy). Then, she followed a doctoral training in Pharmacology, at Catholic University of Rome, Italy. She worked for 2 years as Postdoctoral Research Fellow at Le Centre Hospitalier of Laval University (Quebec, Canada) and at the Department of Pharmacology of Merck Frosst (Kirkland, Quebec, Canada).

 She continued her academic career at “G. d' Annunzio” University, School of Medicine, Chieti, Italy, where she is currently Professor of Pharmacology and Head of the Laboratory of Systems Pharmacology and Translational Therapeutics at the Center of Excellence on Aging and Translational Medicine (CeSI-MeT).

 In 2009 she was Guest professor of Pharmacology at Goethe-Universität Frankfurt am Main (Germany). She is a member of the Italian Society of Pharmacology and she received the Upjohn Award (1981), the "Henry Christian" Award (1991) and was the winner of the 2018 International Aspirin Foundation Senior Science Award. In 2013, she received a special prize awarded by the Committee for the Promotion of Female Entrepreneurship of Abruzzo Region (Italy).

She is one of the Top Italian Women Scientists (TWIS) which includes the scientists with high impact publications. Her scientific activity is documented by 170 peer-reviewed publications in international journals ranked in the Journal Citation Reports, and 21 chapters in national-international books. Her cumulative citation index (H-index) is 56, 11831 citations.

Short statements of expertise 

  •  Her research focuses on the study of the role of eicosanoids in inflammation, cancer and                                  cardiovascular disease.
  •  She has contributed to the development of biomarkers predictive of the impact of NSAIDs on COX-1            and COX-2 activities in vitro, ex vivo and in vivo which have been essential to read-out the clinical                consequences of selective and nonselective inhibition of COX-isozymes in humans.
  •  Her recent studies have allowed to clarify the determinants of NSAID toxicity for the gastrointestinal            and cardiovascular systems which will be important for the development of personalized treatments in        humans.
  •  She is performing an intense research activity with the aim of identifying the mechanisms of the anti-          tumorigenic effects of antiplatelet agents, with particular interest in clarifying the mechanism of action        of aspirin. To realize these aims her research group is integrating basic and clinical research in                      different biological systems using the “Omics” approach.